This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated
